Aspartylglucosaminidase
Aspartylglucosaminidase (AGA) is an enzyme that plays a crucial role in the lysosomal degradation of glycoproteins. This enzyme specifically catalyzes the hydrolysis of the N-acetylglucosamine-asparagine linkage in the oligosaccharide moieties of glycoproteins. The activity of aspartylglucosaminidase is essential for the normal turnover and recycling of glycoproteins within cells.
Function
Aspartylglucosaminidase is located in the lysosome, an organelle responsible for breaking down various macromolecules. By cleaving the bond between asparagine and N-acetylglucosamine, AGA facilitates the degradation of glycoproteins, which are proteins with carbohydrate groups attached to them. This process is vital for the maintenance of cellular homeostasis and the regulation of glycoprotein levels within the body.
Genetic and Molecular Basis
The gene responsible for encoding aspartylglucosaminidase is located on human chromosome 4. Mutations in this gene can lead to a deficiency in AGA activity, resulting in the accumulation of glycoproteins and their fragments within lysosomes. This accumulation is the basis of a rare inherited disorder known as Aspartylglucosaminuria (AGU).
Aspartylglucosaminuria
Aspartylglucosaminuria is an autosomal recessive lysosomal storage disorder characterized by a deficiency in the enzyme aspartylglucosaminidase. Individuals with this condition exhibit a wide range of symptoms, including developmental delay, skeletal abnormalities, and coarse facial features. The diagnosis of AGU is confirmed through genetic testing and the measurement of AGA activity in leukocytes or fibroblasts.
Treatment and Research
Currently, there is no cure for aspartylglucosaminuria. Treatment focuses on managing symptoms and improving the quality of life for affected individuals. Research into gene therapy and enzyme replacement therapy offers hope for future treatments that may address the underlying cause of AGU by restoring AGA activity.
See Also
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD